1Haffty BG,Yang Q,Reiss M,et al.Local-regional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer[].Journal of Clinical Oncology.2006
2Carey LA,Perou CM,Livasy CA,et al.Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[].Journal of the American Medical Association The.2006
3Dent R,Trudeau M,Pritchard KI,et al.Triple-negative breast cancer: clinical features and patterns of recurrence[].Clinical Cancer Research.2007
4Rouzier R,Perou CM,Symmans WF,et al.Breast cancer molecular subtypes respond differently to preoperative chemotherapy[].Clinical Cancer Research.2005
5Kandel MJ,Stadler Z,Masciari S,et al.Prevalence of BRCA1mutations in triple negative breast cancer (BC)[].Proceedings of the American Society of Clinical Oncology.2006
6Carey LA,Dees EC,Sawyer LR,et al.The triple negative paradox:Primary tumor chemosensitivity of the basal-like breast cancer phenotype[].Breast Cancer Research.2004
7Liedtke C,Mazouni C,Hess KR,et al.Response and Outcome After Neoadjuvant Therapy in Patients with Triple Negative vs.non-TN Breast cancer[].Journal of Clinical Oncology.2008
8Chang HR,Slamon D,Gombein JA et aL.Preferential pathologic complete response (pCR)by triple-negative (-)breast cancer to neoadjuvant docetaxel (T)and carboplatin (C)[].Journal of Clinical Oncology.2008
9Burnell MJ,Connor EM,Chapman JW.Triple-negative receptor status and prognosis in the NCICCTG MA.21 adjuvant breast cancer trial[].Journal of Clinical Oncology.2008
